Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coloplast As ADR (OP:CLPBY)

6.772 -0.198 (-2.84%)
Streaming Delayed Price Updated: 11:18 AM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coloplast As ADR

News headline image
Full Transcript: Coloplast Q3 2026 Earnings Call ↗
Coloplast (OTC:CLPBY) released third-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call... 
Via Benzinga
Topics Earnings
News headline image
A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus
Issued on behalf of Conexeu Sciences Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
CLPBY Stock Earnings: Coloplast Reported Results for Q3 2024 ↗
Coloplast just reported results for the third quarter of 2024. 
Via InvestorPlace
News headline image
CLPBY Stock Earnings: Coloplast Reported Results for Q2 2024 ↗
Coloplast just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
CLPBY Stock Earnings: Coloplast Reported Results for Q3 2023 ↗
Coloplast just reported results for the third quarter of 2023. 
Via InvestorPlace
News headline image
CLPBY Stock Earnings: Coloplast Reported Results for Q4 2023 ↗
Coloplast just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Short Volatility Alert: Coloplast ↗
On Tuesday, shares of Coloplast (OTC: CLPBY) experienced volatile short activity. After the activity, the stock price went up +0.59% to $13.18. The overall sentiment for CLPBY has been Bullish. 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.